St Jude's pacemaker programmer

The Japanese Ministry of Health, Labor and Welfare (MHLW) has approved St Jude Medical's Merlin patient care system to manage patients implanted with cardiac devices. The universal programmer for cardiac resynchronisation therapy (CRT) devices, implantable cardioverter defibrillators (ICDs) and pacemakers has been approved in the US since April 2006. It is a portable computer that allows doctors to programme the device at the time of implant, retrieve and analyse patient information during routine follow-up visits, and make programming changes to the implanted device. St Paul, Minnesota-based St Jude developed the Merlin patient care system with the information technology company IBM.

The Japanese Ministry of Health, Labor and Welfare (MHLW) has approved St Jude Medical's Merlin patient care system to manage patients implanted with cardiac devices. The universal programmer for cardiac resynchronisation therapy (CRT) devices, implantable cardioverter defibrillators (ICDs) and pacemakers has been approved in the US since April 2006. It is a portable computer that allows doctors to programme the device at the time of implant, retrieve and analyse patient information during routine follow-up visits, and make programming changes to the implanted device. St Paul, Minnesota-based St Jude developed the Merlin patient care system with the information technology company IBM.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

Final Chance To Have Your Say: Take Our Reader Survey This Week

 
• By 

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 
• By 

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, content format or the method in which you receive and access Medtech Insight, or if you love it how it is, now is the time to have your voice heard.

Patients With Movement Disorders Will Benefit From Medtronic’s Expanded MRI Labeling For DBS

 
• By 

Medtronic announced it received expanded MRI labeling for its DBS systems, which is critical, given that almost 70% of all DBS-eligible patients will likely need an MRI at some point in their care, says Ashwini Sharan, CMO for Medtronic Neuromodulation.

Podcast: Lung Life AI CEO Shares Regulatory And Reimbursement Journey For Lung Cancer Diagnostic

 

In this episode, Medtech Insight reporter Natasha Barrow speaks to LungLife AI CEO Paul Pagano. Lung Life AI is a US-based AIM-listed medical technology company that has developed a liquid biopsy test for the early detection of lung cancer called Lung LB. Pagano runs through the highlights of Lung Life AI journey to date and its future ambition for a strategic partnership. He also provides advice to similar diagnostic companies seeking reimbursement andcompliance with the US FDA Lab Developed Test ruling.

More from Medtech Insight

Terumo’s $1.5Bn Buyout Of OrganOx Vaults Company Into Organ Preservation Market

 
• By 

Terumo will acquire OrganOx for about $1.5bn, adding the only FDA-cleared liver normothermic perfusion device to its portfolio. Analysts don’t expect the buyout to have a significant impact on competition, but the deal marks a strategic shift for Terumo into transplant medicine.

Study Finds Public Companies Behind Most Recalled AI Devices

 
• By 

A Johns Hopkins University study found publicly traded companies are responsible for 90% of recalled AI-powered medical devices. The study attributes this link to lower clinical validation, especially among smaller companies, and advocates for increased clinical trials to enhance device safety.

Four-Year Waits, 60-Page NCDs: Consultant Urges Medicare Overhaul

 
• By 

Medicare’s device coverage process is “a system in crisis,” consultant Bruce Quinn warned at the NextGen Dx Summit. He criticized bloated NCDs, stalled advisory committees, and years-long delays, urging CMS to streamline LCDs and adopt a six-month “fast-track” model to speed innovation access.